A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers

Breast cancers lacking estrogen receptor (ER) expression have an adverse prognosis and fail to respond to endocrine therapy. We have identified a transcriptional enhancer in the human ER gene which is differentially active in ER-positive (ER(+)) and ER-negative (ER(-)) human breast cancer cell lines. Enhancer function was mapped to a 35-bp element located from -3778 to -3744 upstream of the major human ER mRNA start site, which we have termed ER-EH0 (for estrogen receptor enhancer). Gel retardation assays with ER(+) and ER(-) cell lines identified multiple DNA-protein complexes which specifically form on this enhancer. One of these complexes could be supershifted by anti-Jun or anti-Fos antibodies, identifying it as an AP-l-containing complex. Methylation interference assays suggest binding of factors to both the AP-1 site and adjacent base pairs, Enhancer activity requires both the AP-1 site and these adjacent sequences, Mutations introduced into ER-EH0 and the recently described proximal promoter element ERF-1 in the context of the full-length promoter confirm ER-EH0 as the dominant cia-acting element involved in differential ER expression.